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Abstract 
Alzheimer's disease (AD) is a neurodegenerative disorder 
with no known cure which has a strong impact on patients 
and their caregivers. Current treatments for AD can slow the 
disease progression, but cannot reverse the damage that has 
already been done, resulting in some level of lifelong disabil-
ity for affected patients. The use of lithium has shown prom-
ising results in mice models of AD. While animal models have 
produced positive results, additional human trials need to be 
conducted in order to determine a place for lithium in Alz-
heimer's disease therapy. Pharmacists should be aware of 
this potential new use of lithium since this is a drug that re-
quires intensive monitoring and has multiple drug interac-
tions. By having knowledge of the rationale for using lithium 
in Alzheimer's disease, pharmacists can be better equipped 
to counsel patients and their caregivers. 
Background 
Alzheimer's disease (AD) is a progressive neurodegenerative 
disorder which affects 2.4 to 5.1 million people in the United 
States, according to the National Institute on Aging.1 AD is not 
a normal part of aging; rather it is a disease causing dementia 
characterized by a loss of cognition. This loss of cognition 
may be serious enough to affect a patient's activities of daily 
living (ADLs). AD affects the most recent memories first be-
fore progressing to other areas of the brain. Not only is AD 
the leading cause of dementia in the elderly in America, but it 
has also been tied to the deterioration of general cognitive 
skills,1.2 Unfortunately, treatment of AD is limited to drugs 
which function only to slow the progression of the disease 
and abate symptoms, as there is no cure for the disease at the 
present time.1 AD has been sub-classified into seven stages 
by the Alzheimer's Association based on the most common 
symptoms of the disease as it progresses. AD progression 
may vary greatly, and patients may not experience the same 
symptoms at any given stage of the disease. However, these 
disease stage classifications may be helpful in determining 
the course of action a practitioner may choose to take if a 
patient presents with some of the symptoms along the con-
tinuum of progressive cognitive impairment. 
Stage 1: No impairment (normal function) 
Patient experiences no memory problems and 
does not show signs or symptoms of dementia. 
Stage 2: Very mild cognitive decline (age-related or the 
earliest signs of Alzheimer's disease) 
Memory lapses, such as forgetting familiar words, 
are common but clinical examination does not 
show signs of dementia. 
Stage 3: Mild cognitive decline (early-stage Alzheimer's 
may be diagnosed in some individuals with 
these symptoms) 
Clinical examination may detect problems in con-
centration or memory; friends, family or co-
workers may begin to notice difficulties such as 
problems remembering what was just read, in-
creasing trouble organizing or difficulty perform-
ing tasks in social or work settings. 
Stage 4: Moderate cognitive decline (mild or early-
stage Alzheimer's disease) 
Medical review should be able to detect clear 
problems in several areas such as forgetfulness of 
recent events, impaired ability to perform chal-
lenging mental arithmetic, forgetfulness of one's 
own history or becoming moody in socially or 
mentally challenging situations. 
Stage 5: Moderately severe cognitive decline (moderate 
or mid-stage Alzheimer's disease) 
Patients may need help performing ADLs and gaps 
in memory and thinking are noticeable. Individu-
als may be unable to recall their address or tele-
phone number, become confused about where 
they are or what day it is, or have trouble with less 
challenging math, but may still remember signifi-
cant details about themselves and their family. 
Stage 6: Severe cognitive decline (moderately severe or 
mid-stage Alzheimer's disease) 
Memory and thinking ability will continue to 
worsen and patients may need help with ADLs, 
which include use of the bathroom or dressing 
properly. Patients may lose awareness of their 
own surroundings, be able to distinguish faces of 
family members but not be able to remember 
names, experience behavioral or personality 
changes, or experience major changes in sleep pat-
terns. 
Stage 7: Very severe cognitive decline (severe or late 
stage Alzheimer's disease) 
Individuals lose the ability to respond to their en-
vironment, carry on a conversation and eventually 
control movement. Patients need help with most 
of their daily activities and no longer recognize 
their closest relatives and friends. 
Etiology of Alzheimer's Disease 
AD is characterized clinically by three main hallmarks which 
lead to decreased cholinergic neurotransmission: buildup of 
amyloid-~-peptides (A~), neurofibrillary tangles from a hy-
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perphosphorylated tau protein and degeneration of choliner-
gic neurons.1.3-5 Extracellular buildup of AP originates from 
the cleavage of the amyloid precursor protein (APP).2,3 A~ 
then accumulates in the brain and forms neuritic plaques 
which slow the brain's cognitive function by inhibiting neu-
rologic pathways.3.4 Alteration in synaptic function may also 
be due to the intracellular neurofibrillary tangles from a hy-
perphosphorylated tau protein, a microtubule associated 
protein, which misfolds and disassembles from microtubules 
when hyperphosphorylated. This misfolding and disassocia-
tion of the tau protein in the brain forms aggregates and 
therefore alters overall synaptic transmission and func-
tion.3,6,7 Additionally, levels of brain-derived neurotrophic 
factor (BDNF) and mRNA are diminished in both the brain 
and serum of Alzheimer's patients.6 BDNF is a neurogenera-
tive agent which plays an important role in neuronal growth, 
survival and differentiation. Low levels in the body may re-
sult in neurodegeneration and a decrease in neurotrophic 
function. Buildup of AP neuritic plaques from the cleavage of 
APP, neurofibrillary tangles from an aggregation of disassoci-
ated tau protein and a decrease of serum BDNF have been 
shown to decrease the rate and efficiency of cholinergic neu-
rotransmission.3·4·6 
The increased expression of glycogen synthase kinase-3p 
(GSK-3P) is an important consideration in AD because GSK-
3~ has been shown to be a predominant tau-kinase in the 
brain and has more recently been shown to be involved with 
the formation of Ap.5.8 GSK-3P is a serine-threonine kinase 
responsible for phosphorylating both tau and APP, and is a 
necessary component of a variety of intracellular signaling 
pathways.4 Over-expression of GSK-3~ may cause hyper-
phosphorylation of tau and APP which results in aggregation 
of extracellular neuritic plaques ;is well as intracellular neu-
rofibrillary tangles, which are both clinical markers of AD.3,4 
Due to this relationship of increased expression of GSK-3~ 
and the major clinical markers of AD, a variety of studies 
have looked at the effects of dysfunctional GSK-3P on the 
progression and treatment of the disease by testing the inhi-
bition of GSK-3p. Studies have shown that over-expression of 
GSK-3~ is associated with neurodegeneration and aggrega-
tion of neurofibrillary tangles similar to AD and other demen-
tias, making this protein a primary drug target for AD.3-5,8 
Lithium 
Lithium has been used in the treatment of mood disorders 
since 1949 and has remained first-line therapy of bipolar 
disorders up to present day.5.6 It has known neuroprotective 
effects, but the overall mechanism is still largely unknown. It 
has been shown to inhibit GSK-3P both directly and indi-
rectly which is the reason for introducing lithium into the 
Alzheimer's population as a possible treatment. 4,S,8 Direct 
inhibition of GSK-3~ occurs when lithium competes with the 
magnesium ion for one of two magnesium binding sites on 
the kinase.5 While a variety of drugs appear to have this 
direct inhibitory mechanism, the indirect inhibition of GSK-
3 p remains exclusive to lithium. The proposed mechanism of 
indirect inhibition is that lithium increases the N-terminal 
serine phosphorylation of GSK-3p, thereby allosterically 
inactivating the enzyme. The specific mechanism by which 
lithium exerts this indirect inhibition is still under 
investigation. 
This combination of direct and indirect inhibition of the GSK-
3p enzyme has been shown to protect against AP injury or 
neurotoxicity and has also been shown to reduce the amount 
of phosphorylated tau in vitro and in vivo.z.s Lithium is a com-
plex molecule with many cellular effects, a high potential for 
toxicity and a narrow therapeutic range. Even levels within 
the narrow therapeutic range of 0.5 to 1.5 mmol/L may re-
sult in adverse effects such as diabetes insipidus, thyroid tox-
icity and imbalances in calcium and other electrolytes.8 
Therefore, there is a need to monitor serum levels via blood 
draws every four to five days during initial therapy. There 
are also strict dosage adjustments for patients with renal 
impairment because of the high potential for adverse effects.9 
Alzheimer's and Lithium 
It has been observed that there is a reduced prevalence of AD 
in bipolar patients on lithium therapy.6 This observed corre-
lation has recently led researchers to study the possibility of 
using lithium to treat Alzheimer's Disease. Mouse and cul-
tured nerve studies have been useful in gathering significant 
data. However, human trials have been a little more difficult 
to assess and cause a number of questions to be raised upon 
analyzing the results. 
Mice trials have helped to illustrate the effects of GSK-3~ on 
AD. In mice, over-expression of GSK-3P induces neurodegen-
eration. Results showed a reduction of A~ in the hippocam-
pus and cortex, less neuritic aggregates, less plaque buildup 
and decreased glial inflammatory reactions in mice treated 
with lithium to inhibit GSK-3~ expression compared to con-
trol mice.3 The mice treated with lithium not only showed 
significant reduction in AD markers, but also showed im-
provement of spatial memory. This data suggests lithium 
may have an important role in slowing progression of AD. 
Lithium has also been seen to induce BDNF production in 
cultured neurons and rodent models.6 As previously stated, 
BDNF protects neurons from injury. In postmortem analyses 
of AD patients, BDNF levels were diminished in brain and 
serum samples. A randomized, patient-only blinded human 
trial was performed treating AD patients for 10 weeks with 
lithium. The results showed a significant increase in BDNF 
serum levels compared to baseline. 
The in vitro evidence shows lithium significantly reduces AD 
characteristics and markers.3,6,8 Despite the fact that studies 
were conducted for an appropriate length, the disease state 
itself has resulted in a high dropout rate making the data col-
lected difficult to use in assessing significance. One random-
ized trial of 27 patients lasted 12 weeks and measured BDNF 
serum levels and cognitive impairment using the Alzheimer's 
Disease Assessment Scale-cognitive subscale (ADAS-Cog) 
method.6 Patients were started on lithium sulfate 42 mg 
twice daily and researchers used a six-week titration phase 
to reach targeted serum levels of 0.5 to 0.8 mmolf L. There 
were two dropouts in this study; one was discontinued at 
week eight for unknown reason beyond unwillingness to 
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continue, one other dropout was reported due to a serious 
adverse event of severe aggression and hallucinations at 
week seven. The results reported a statistically significant 
increase in BDNF serum levels and a decrease in cognitive 
impairment with lithium treatment compared to the placebo 
group. An open-label trial was conducted of 22 patients last-
ing longer than 12 months looking at the feasibility of using 
lithium in treating AD.B Patients were instructed to continue 
their daily medication regimen, but these specific medica-
tions were not documented. A specific dosing regimen for 
lithium was not established during the trial. Patients were 
started on low dose lithium carbonate 100 mg and serum 
levels were assessed every two weeks to reach target levels 
of 0.3 to 0.8 mmoljL. They started the screening process 
with 480 patients and excluded 458 patients for failing to 
meet entry screening lab levels, not wanting to participate 
due to frequency of assessment, compliance issues and pa-
tients with a concomitant illness or therapy that was contra-
indicated with lithium treatment. There were a total of 14 
dropouts in this study, including two deaths unrelated to 
treatment. The other 12 dropouts were due to hospital ad-
missions unrelated to treatment or relatives or investigators 
removing them from treatment. The authors of this trial con-
cluded lithium was safe when dosages were kept within the 
therapeutic range and that side effects were mild and not the 
main cause of withdrawal from the study. However, with the 
high dropout rate and only eight patients completing the 
trial, these conclusions are debatable. Although there is a 
significant amount of literature available on this topic, more 
randomized, controlled human trials should be performed in 
AD patients even though the in vitro and in vivo studies sug-
gest lithium may decrease the characteristics and disease 
progression of AD. 
Pharmacy Implications and Counseling 
Since AD is a disease state of the elderly, it is important to 
monitor side effects, as they may be greater in the elderly 
population due to comorbid disease states, interactions with 
other drugs and a higher probability of dehydration. It is im-
portant to counsel patients on the importance of staying hy-
drated in order to avoid kidney stones and toxicity. Due to 
the narrow therapeutic range of lithium, it is important to 
review a patient's current medication profile and history of 
present illness in order to assess potential precautions. Some 
precautions with the use of lithium include thiazide diuretics, 
thyroid disease, renal impairment and heart disease.s.9 It is 
also important to make sure the dosing schedule results in 
drug concentrations within the therapeutic range to avoid 
neurotoxic effects. Pharmacists and physicians also should 
ensure labs are being drawn as recommended in order to 
adjust the dose as necessary. Lithium serum level monitor-
ing, while imperative, is a major deterrent from use since it 
requires frequent blood draws which may be undesirable to 
the patient.9 
Lithium treatment is focused on slowing disease progression, 
but patients may continue to exhibit symptoms associated 
with AD. Health care professionals can help treat some of the 
symptoms of AD to make the patient more comfortable. For 
example, hand tremors can be treated with propranolol, 
while a non-thiazide or potassium sparing diuretic can be 
used for the adverse effects of diabetes insipidus.1,9 Lithium 
has also been proven to help treat agitation and aggression 
associated with dementia.7 Overall, the literature suggests 
lithium may be a helpful adjunct for slowing the progression 
of AD. When used with the appropriate therapeutic range, it 
may prevent progression and possibly reverse AD character-
istics. 
Conclusion 
There is still no cure for AD; it is a progressive neurodegen-
erative disorder affecting the most recent memories first and 
working its way to other areas of the brain. The use of lith-
ium in slowing the progression of AD has been successful in 
mice studies and more research is being done to see if similar 
results will be seen in human trials. Researchers believe lith-
ium to display the neuroprotective effects of inhibiting GSK-
3~ and inducing BDNF production; therefore, it may have the 
potential for use early in AD treatment. While lithium may be 
able to help patients with the management of AD, it is impor-
tant that pharmacists check for contraindications, counsel 
patients on staying hydrated and help patients manage their 
AD symptoms to have a better overall quality oflife. 
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